Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

FDA Clears GSK’s Requip XL For Parkinson’s

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Once-daily version is designed to battle generic competitors.

You may also be interested in...



Generic Requip Cleared For RLS

Teva, Mylan, Roxane and Par will market ropinirole for Restless Legs Syndrome; Parkinson's patent expires this month, too.

Requip XL User Fee Date Pushed Back To Second Quarter

FDA needs additional time to review food effect data from GlaxoSmithKline for the once-daily Parkinson's treatment.

GSK Plans Next-Generation Restless Legs Treatment Filing In Q3 2008

U.K. drug maker also is planning to initiate a Phase III program evaluating GSK 1838262 for migraine prophylaxis.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS067910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By